Philadelphia, PA Clinical Trials Report — April 2026

For patients and healthy volunteers in Philadelphia, April 2026 presents a critical window to engage with clinical research, particularly for studies nearing their enrollment deadlines. Across the city, 141 clinical trials are scheduled to conclude within the next 90 days. This urgency extends to healthy individuals, as 26 of these rapidly closing studies are still actively seeking participants without specific health conditions. Those interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face limited time to join research. Trials focused on a range of health challenges are among those with enrollment closing soon. Conditions with trials concluding within 90 days include:

• Opioid use disorder (4 trials)
• Gastric cancer (3 trials)
• Stage IV lung cancer AJCC V8 (2 trials)
• Gestational diabetes (2 trials)
• Myelodysplastic syndromes (2 trials)
• Primary graft dysfunction (2 trials)
• Cancer (2 trials)
• Ascites hepatic (2 trials)
• Deep venous thrombosis (2 trials)
• Cervical cancer (2 trials)

New Opportunities in Philadelphia Research

This April, Philadelphia welcomed 14 new clinical trials, a decrease from the 25 trials that opened in March 2026. Despite this fluctuation, the city remains a significant hub for medical research, with a total of 1,831 clinical trials currently recruiting across 573 research facilities.

For individuals without a specific medical condition, there are opportunities to contribute. 2 of the new trials launched this month are actively seeking healthy volunteers. Overall, Philadelphia currently has 177 trials recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

New trials this month are exploring a range of conditions, including vascular anomalies, adolescent congenital heart disease, apical periodontitis, cancer, chronic insomnia, and endodontic disease. Drug trials lead the new openings with 6 studies, followed by 3 behavioral trials and 2 device trials.

Spotlight on Notable New Trials

April brings several high-profile new trials to Philadelphia, including significant Phase 2, Phase 3, and Phase 4 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across various health challenges.

• The University of Pennsylvania is sponsoring NCT07542756, "SMART Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults." This Phase 4 study, aiming for 1,200 participants, assesses the effectiveness, safety, and durability of common prescription and over-the-counter insomnia medications.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy for pancreatic cancer.
• The VA Office of Research and Development is leading NCT07549178, "Care Coordination and Passive Mobile Data Monitoring to Improve Mental Health Care." This study involves 400 participants and aims to improve care for individuals with serious mental illness through ongoing monitoring and coordination.
• Carelon Research is initiating NCT07525843, "A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study." This trial, designed for 390 participants, investigates whether an online wellbeing program can help teens with congenital heart disease manage stress.
• The National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring NCT07549503, "Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation." This Phase 2 study involves 100 participants and aims to determine the efficacy of 50 percent immunosuppression reduction in liver transplant recipients.

Philadelphia's Research Powerhouses

Philadelphia is home to some of the nation's leading research institutions, which consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Pennsylvania (321 trials)
• Children's Hospital of Philadelphia (263 trials)
• Thomas Jefferson University Hospital (123 trials)
• Fox Chase Cancer Center (112 trials)
• Thomas Jefferson University (89 trials)
• Hospital of the University of Pennsylvania (80 trials)
• Temple University Hospital (46 trials)
• The Children's Hospital of Philadelphia (36 trials)
• Temple University (35 trials)

These institutions offer a broad spectrum of research, from pediatric care at Children's Hospital of Philadelphia to oncology at Fox Chase Cancer Center and comprehensive medical fields across the University of Pennsylvania and Thomas Jefferson University systems.

Expanding Your Search: Beyond Philadelphia

While Philadelphia offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Pennsylvania. Cities with active trials include Pittsburgh (9 trials), Cranberry Township (2 trials), Hershey (1 trial), Kingston (1 trial), Erie (1 trial), West Conshohocken (1 trial), Yardley (1 trial), and York (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 14 new trials launched this month, 5 include children and 9 include older adults, ensuring that various age groups have opportunities to contribute to medical science. Academic institutions continue to play a vital role in Philadelphia's research ecosystem, with the University of Pennsylvania, Children's Hospital of Philadelphia, and the VA Office of Research and Development sponsoring the majority of new trials. Industry sponsors like Incyte Corporation are also driving significant research efforts.

As we move further into spring, Philadelphia's robust research community will continue to drive medical innovation, with ongoing enrollment in significant trials and the exploration of new therapeutic strategies across a wide range of health conditions.